We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

26 hedge funds and large institutions have $53.1M invested in Trillium Therapeutics Inc. in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

102% more capital invested

Capital invested by funds: $26.2M → $53.1M (+$26.8M)

50% more call options, than puts

Call options by funds: $256K | Put options by funds: $171K

30% more funds holding

Funds holding: 20 → 26 (+6)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

Holders
26
Holders Change
+6
Holders Change %
+30%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
7
Reduced
6
Closed
4
Calls
$256K
Puts
$171K
Net Calls
+$85K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$18M
2
NMC
NEA Management Company
Maryland
+$1.66M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.3M
4
AG
Artal Group
Luxembourg
+$1.24M
5
Deutsche Bank
Deutsche Bank
Germany
+$906K

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$2.21M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$1.21M
3
AIC
AWM Investment Company
New York
-$915K
4
TCM
Tekla Capital Management
Massachusetts
-$414K
5
CS
Candriam SCA
Luxembourg
-$133K
Name Holding Trade Value Shares
Change 		Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$15.8M +$18M +2,173,000 New
NMC
2
NEA Management Company
Maryland
$9.06M +$1.66M +200,000 +19%
AIC
3
AWM Investment Company
New York
$7.08M -$915K -110,480 -10%
CAM
4
Cormorant Asset Management
Massachusetts
$4.38M – – –
TCM
5
Tekla Capital Management
Massachusetts
$3.29M -$414K -50,000 -10%
BBA
6
Baker Bros. Advisors
New York
$2.97M -$36.2K -4,374 -1%
NLVP
7
New Leaf Venture Partners
New York
$2.93M – – –
Victory Capital Management
8
Victory Capital Management
Texas
$1.6M +$604K +72,950 +50%
Morgan Stanley
9
Morgan Stanley
New York
$1.17M +$828K +99,985 +164%
Renaissance Technologies
10
Renaissance Technologies
New York
$1.14M +$1.3M +157,022 New
AG
11
Artal Group
Luxembourg
$1.09M +$1.24M +150,000 New
Deutsche Bank
12
Deutsche Bank
Germany
$835K +$906K +109,406 +1,860%
CS
13
Candriam SCA
Luxembourg
$683K -$133K -16,000 -15%
Creative Planning
14
Creative Planning
Kansas
$191K – – –
Wells Fargo
15
Wells Fargo
California
$189K +$79.1K +9,550 +58%
Citadel Advisors
16
Citadel Advisors
Florida
$180K +$204K +24,622 New
OAM
17
Oxford Asset Management
United Kingdom
$165K +$183K +22,097 New
VF
18
Virtu Financial
New York
$144K +$165K +19,898 New
Millennium Management
19
Millennium Management
New York
$91K +$6.48K +782 +7%
Barclays
20
Barclays
United Kingdom
$76K +$87K +10,500 New
LTFS
21
Ladenburg Thalmann Financial Services
Florida
$25K +$29K +3,500 New
1832 Asset Management
22
1832 Asset Management
Ontario, Canada
$18K +$20.7K +2,500 New
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$4K -$2.38K -288 -32%
TRCT
24
Tower Research Capital (TRC)
New York
$3K +$2.04K +247 +124%
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$456 -$22.1K -2,666 -98%
1
2

TRIL Hedge Fund Activity: Q4 2017 in Review

26 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2017, worth a combined $53.1M — up 102% from $26.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new TRIL positions and 4 closed out — a net gain of 6 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $18M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $2.21M sold.

  • 26 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2017, up from 20 in Q3 2017.
  • Funds reported $53.1M of Trillium Therapeutics Inc. stock for Q4 2017, up 102% quarter-over-quarter.
  • 10 funds opened new Trillium Therapeutics Inc. positions in Q4 2017 and 4 closed out, a net change of +6 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q4 2017 was Matrix Capital Management Company, an estimated $18M added.
  • The largest Trillium Therapeutics Inc. seller in Q4 2017 was Janus Henderson Group, an estimated $2.21M sold.

Based on aggregated 13F filings for Q4 2017.